What Human Factors Actually Costs (and What Drives the Number)

What Human Factors Actually Costs (and What Drives the Number)

If you've been searching the web for what a human factors program costs so you can plan a budget, you've probably come upon a lot of pages that promise an answer and then just push you toward a discovery call. It's frustrating. Here are my thoughts on honest ranges, what drives them, and a few things to look out for, whether you're a founder budgeting for the first time or an engineering lead deciding what to keep in house.

One note before the numbers. These are market ranges assembled from published industry data and typical scope, not a quote. Your actual cost depends on device complexity, number of user groups, and use-related risk. But they're honest, and they'll keep you from being blindsided.

The cost breakdown

Expert review or heuristic evaluation, the lightest formative activity, runs roughly $15,000 to $30,000. This is a human factors specialist evaluating your interface against known principles before you put it in front of real users. It's the cheapest way to catch obvious problems early.

Formalized formative usability testing, the iterative rounds you run during design with real representative users, runs $60,000 to $120,000 and about 1 to 3 months depending on rounds and user groups. This is where you learn what actually confuses people and fix it while fixing it is still cheap.

Summative validation, the study you submit to the FDA, typically lands in the low six figures and takes 4 to 6 months. The FDA guidance effectively requires at least 15 participants per distinct user group, and that group/participant count is one of the biggest single cost drivers in the whole program.

Stack those budgets and durations together, and keep in mind they occur serially, with time between for engineering and quality to do their work. Simpler single-user-group devices sit at the lower end. Complex systems land well above it.

Labor versus pass-through costs, and why the difference matters

The above is pretty straightforward labor costing. But here's something that can be a surprise, either by its existence or its magnitude. A human factors program carries significant pass-through costs that sit on top of labor, and if you don't account for them separately, your budget will come up short.

The biggest one is participant honorariums. You compensate every person who takes part in a study, and the amount scales with how hard they are to recruit. Consumers might run $75 to $150 per session. Nurses and allied health professionals, $150 to $400. Specialist physicians like surgeons or interventional cardiologists can be $500 to $1,500 or more.

Let's look at the arithmetic on a summative study. 15 participants per user group (FDA requirement) across three groups is 45 sessions. At $750 each for specialists, that's roughly $34,000 in honorariums alone, separate from the labor to run the study. Add recruitment agency fees for hard-to-reach groups, which are common and can run several hundred to over a thousand dollars per recruited participant, and it can become a real financial strain when you have very limited funds or are reviewed on how you stick to budget.

When you compare proposals, check whether honorariums and recruitment are baked into the quoted number or billed separately. Neither approach is wrong. You just need to know which one you're looking at to compare quotes accurately.

What actually drives the number

Four things move the cost more than anything else.

The number of user groups is the biggest lever. The FDA expects at least 15 participants per group, so a device used by nurses, patients, and caregivers effectively triples a big chunk of both your labor and your honorarium cost versus a device with a single user group. Every distinct user type you add is another full cohort to recruit, compensate, test, and analyze.

Participant recruitment difficulty is the one teams underestimate most. Recruiting 15 general consumers is straightforward. Recruiting 15 interventional cardiologists, or 15 patients with a specific rare condition, is slow and expensive, and recruitment timelines often drive the schedule more than the testing itself.

Critical task complexity determines depth. If your use-related risk analysis identifies many critical tasks, tasks where a use error could cause harm, your summative study has to rigorously evaluate every one of them. More critical tasks means longer sessions, more detailed data capture, and more analysis.

Device readiness for summative testing matters more than people expect. Summative testing has to be run on production-equivalent devices. If your device isn't there yet, you either wait or you build production-equivalent units specifically for testing, which is its own cost.

The parts teams forget to budget for

The testing sessions are the visible cost. The work around them is where budgets slip.

Use-related risk analysis has to come first. You can't design a meaningful study until you've formally identified who uses the device, in what environment, and which tasks could cause harm if done wrong. This analysis drives everything downstream.

Storyboarding and use scenario development translate that risk analysis into the actual tasks participants will perform. Done well, this is real engineering work, not a formality.

Protocol development, and a possible FDA Pre-Submission to align with the agency on your approach before you spend the money on summative testing, adds one to two months but can save you from running an expensive study the FDA won't accept.

IRB review, if required, adds time. Moderator and analyst time, video capture and analysis, and the final human factors report that ties the whole thing together for your submission all have real costs that sit outside the headline testing line item.

The cost of skipping it

This all sounds expensive, but the real money is lost when you discover a use problem after your design is locked, or after a rejected FDA submission, or after a usability issue contaminates a clinical trial or triggers an adverse event.

The FDA has been explicit that training and warnings are not adequate controls for critical tasks. You can't label and warn your way out of a design people innately use incorrectly. If summative testing reveals a critical-task failure, you're redesigning late, when changes are most expensive, and re-running the study.

Formative work exists precisely to prevent that. Teams that invest early and iteratively almost always spend less in total than teams that treat human factors as a validation checkbox at the end.

For early-stage teams: budget for human factors from day one, not as a pre-submission line item. Even a modest expert review early can change design decisions while they're still cheap to change. Investors who know medtech will ask about your HF plan, and "we'll do it before submission" is a weaker answer than "here's what our formative work already told us."

For engineering leads and program directors at established companies: the question is usually capacity and objectivity, not capability. Outside HF support makes sense when internal teams are at capacity, when you need independent evidence for a submission, or when a program needs specialized recruitment or facilities you don't want to build in house for a single project. The ranges above are a reasonable benchmark for whether an external program is priced fairly.

Human factors is not free and it is not fast. But it is an investment in device development that reliably pays for itself, because the alternative is paying more, later, when your options are worse.

If you're mapping out a human factors program and want a second opinion on scope or budget, contact us to set up a call.